Two Years on From Its Launch, How Has the UPC Impacted European Patent Litigation in the Life Sciences Sector?

Why It Matters

The UPC’s evolving jurisprudence gives life‑science firms clearer, pan‑EU enforcement tools, but also raises exposure to cross‑border claims, demanding proactive patent and litigation planning.

Key Takeaways

• Over 480 life‑science patents litigated since UPC launch
• UPC courts favor holistic claim interpretation, limiting expert dominance
• Provisional measures granted months before launch, preserving crucial evidence
• Long‑arm jurisdiction enables single UPC action against non‑member states
• Medical‑device injunctions weigh life‑saving status alongside infringement

Pulse Analysis

The Unified Patent Court’s jurisprudence has matured rapidly, especially around patent validity. By treating claim construction as a legal exercise that must consider the description and drawings, the UPC reduces reliance on party‑appointed experts and aligns with European Patent Office standards. Its inventive‑step analysis now demands a holistic view of the claim, emphasizing realistic starting points and a "would, not could" test, which raises the evidentiary bar for challengers. Similarly, the court’s stance on added matter and sufficiency reflects a balanced approach that protects genuine innovation while preventing over‑broad claims.

Practically, the UPC’s rulings on provisional measures and imminent infringement are reshaping enforcement tactics. Courts now grant ex parte orders months before a generic or medical‑device launch, provided patentees show a high likelihood of validity and a risk of evidence loss. This early intervention helps preserve critical data, such as manufacturing records or EMA submissions, and streamlines the path to preliminary injunctions. For medical devices, the court weighs the life‑saving nature of a product against infringement, signaling that injunctions may be tempered when no therapeutic alternatives exist.

Perhaps the most strategic shift is the UPC’s expanding long‑arm jurisdiction. By allowing a UPC‑domiciled defendant to anchor non‑member entities, a single action can cover infringements in the UK, Switzerland, Turkey and beyond. This creates a powerful tool for rights holders to enforce patents across a broader geographic canvas, but also exposes multinational life‑science firms to heightened litigation risk. Companies must therefore reassess licensing, supply‑chain structures and the role of EU authorised representatives to mitigate potential cross‑border injunctions and damages.